Objectives: Radiation is frequently added to chemotherapy for adjuvant treatment of advanced stage endometrial cancer. Multiple adjuvant therapy sequencing options exist, and little data is available to compare these. We compared outcomes and toxicities after “sandwich” chemoradiation (chemotherapy, then radiation, then chemotherapy) and nonsandwich sequences (chemotherapy then radiation, radiation then chemotherapy, or concurrent chemoradiation). Materials and Methods: We recorded...
Tue Aug 04, 2020 03:00
Pulsed low-dose rate radiation therapy has been shown to reduce normal tissue damage while decreasing DNA damage repair in tumor cells. In a cohort of patients treated with palliative or definitive pelvic reirradiation using pulsed low-dose rate radiation therapy, we observed substantial local control and low rates of toxicity. Supported in part through the NIH/NCI Cancer Center Support Grant P30 CA006927. The authors declare no conflicts of interest. Reprints: Joshua E. Meyer, MD, Department...
Tue Aug 04, 2020 03:00
Background Recent studies have identified increases in cancer incidence among younger adults for some cancers. This study examined incidence trends for 28 cancers in Canada by age and birth cohort from 1983 to 2012. Methods Canadian incidence data for 20 to 84 year‐olds were obtained from the Cancer Incidence in Five Continents Plus database. Age‐period‐cohort modeling was used to estimate the average annual percentage changes (AAPCs) and incidence rate ratios (IRRs) for 10‐year birth cohorts...
Sat Aug 08, 2020 16:25
Background Identifying and addressing caregivers' unmet needs have been suggested as a way of reducing their distress and improving their quality of life. However, the needs of family cancer caregivers are complex in the period of long‐term survivorship in particular because they may diverge as the patients' survivorship trajectory does, and that is what this study investigated. Methods Family cancer caregivers completed prospective, longitudinal surveys 2, 5, and 8 years after diagnosis (n = 633)....
Sat Aug 08, 2020 16:23
Recent years have seen tremendous advances in treating acute myeloid leukemia (AML), largely because of progress in understanding the genetic basis of the disease. The US Food and Drug Administration approved 7 agents for AML in the last 2 years: the first new drugs in decades. In this review, the authors discuss these new approvals in the backdrop of an overall strategy for treating AML today. Treating AML in the modern era requires: 1) access to and use of upfront genetic and cytogenetic testing,...
Fri Aug 07, 2020 20:39
Fri Aug 07, 2020 17:18
Background The risk of breast cancer related to changes in breast density over time, including its regression and persistence, remains controversial. The authors investigated the relationship between breast density and its changes over time with the development of breast cancer in premenopausal and postmenopausal women. Methods The current cohort study included 74,249 middle‐aged Korean women (aged ≥35 years) who were free of breast cancer at baseline and who underwent repeated screening mammograms....
Fri Aug 07, 2020 17:18
Background The phosphatidyl 3‐inositol kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) pathway frequently is activated in patients with urothelial carcinoma (UC). In the current study, the authors performed a phase 2 study evaluating the efficacy of the pan‐isoform class I PI3K inhibitor buparlisib in patients with platinum‐refractory metastatic UC. Methods Two cohorts were recruited: an initial genetically unselected cohort and a subsequent expansion cohort of patients with PI3K/Akt/mTOR...
Fri Aug 07, 2020 17:17
Fri Aug 07, 2020 17:16
Background The development of novel therapies for the myelodysplastic syndromes (MDS) is hampered by inadequate trial recruitment. Factors contributing to low trial accrual are incompletely understood. Methods This study analyzed a pooled patient database from institutions of the US MDS Clinical Research Consortium to compare the characteristics of participants in interventional trials with those of patients who did not enroll in a trial. Results Data were identified for 1919 patients...
Fri Aug 07, 2020 17:15
Background Splenic marginal zone lymphoma (SMZL) is a rare tumor without a uniform treatment approach. The authors describe a large population‐based study evaluating survival outcomes of patients with SMZL according to the treatment received. Methods From the Surveillance, Epidemiology, and End Results database, patients were selected who had SMZL diagnosed from 1999 to 2016. Observation, splenectomy, chemotherapy, and splenectomy with chemotherapy were the evaluated treatment strategies....
Fri Aug 07, 2020 17:11
British Journal of Cancer, Published online: 10 August 2020; doi:10.1038/s41416-020-1023-3The clinical significance of oestrogen receptor expression in breast ductal carcinoma in situ
03:00
British Journal of Cancer, Published online: 10 August 2020; doi:10.1038/s41416-020-1025-1Broccoli extract increases drug-mediated cytotoxicity towards cancer stem cells of head and neck squamous cell carcinoma
03:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Thu Aug 06, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Thu Aug 06, 2020 10:00
Cancer Biotherapy and Radiopharmaceuticals, Ahead of Print.
Thu Aug 06, 2020 10:00
Abstract Immunotherapy as an approach for cancer treatment is clinically promising. CD73, which is the enzyme that produces extracellular adenosine, favors cancer progression and protects the tumor from immune surveillance. While CD73 has recently been demonstrated to be a potential target for glioma treatment, its role in regulating the inflammatory tumor microenvironment has not yet been investigated. Thus, this study explores the immunotherapeutic value of the CD73 blockade...
Fri Aug 07, 2020 21:24
Abstract Myeloid-derived suppressor cells (MDSCs) are widely implicated in negative regulation of immune responses in cancer. Inhibition of class I histone deacetylases (HDAC) with entinostat has anti-MDSC activity. However, as single agent, it did not delay tumor growth in EL4 and LLC tumor models. Here, we found that entinostat reduced immune suppressive activity of only one type of MDSC—polymorphonuclear, PMN-MDSC, whereas it had no effect on monocytic M-MDSC or macrophages....
Fri Aug 07, 2020 21:24
Abstract Background Bladder cancer is diagnosed by the use of several biomarkers, including survivin. This protein has an important role in the cancer progression by controlling the rate of cell apoptosis. Findings show that there is no survivin in normal tissues, whereas the level of survivin expression increases in tumor cells. Design ...
Fri Aug 07, 2020 21:24
Abstract Background Selected patients with advanced non-small cell lung cancer (NSCLC) benefit from immunotherapy, especially immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1) inhibitor. Peripheral blood biomarkers would be most convenient to predict treatment outcome and immune-related adverse events (irAEs) in candidate patients. This study explored associations between inflammation-related peripheral...
Fri Aug 07, 2020 21:24
Abstract Background Over the past few years, immune checkpoint inhibitors have changed the therapeutic landscape of non-small-cell lung cancer (NSCLC). Response to immune checkpoint inhibitors correlates with a pre-existing anti-tumoral immune response. Checkpoint inhibitors have been introduced as second-line therapy and are only very recently used as monotherapy or in combination with chemotherapy as first-line treatment of NSCLC....
Fri Aug 07, 2020 03:00
Abstract Prostate cancer (PCa) continues to be the most common, noncutaneous cancer in men. Bone is the most frequent site of PCa metastases, and up to 90% of patients with advanced PCa develop bone metastases. An altered bone marrow microenvironment, induced by obesity, is a significant mediator for the bone tropism of PCa. However, the specific molecular mechanisms by which obesity causes changes in the bone marrow microenvironment, leading to PCa bone metastasis, are not fully understood. Our...
Sat Aug 08, 2020 18:49
Abstract Precision medicine is a promising strategy for cancer treatment. In this study, we developed an in‐house clinical sequencing system to perform a comprehensive cancer genomic profiling test as a clinical examination and analyzed the utility of this system. Genomic DNA was extracted from tumor tissues and peripheral blood cells collected from 161 patients with different stages and types of cancer. A comprehensive targeted amplicon exome sequencing for 160 cancer‐related genes was performed...
Sat Aug 08, 2020 16:59
Abstract Metabolic alterations are well documented in various cancers. Non‐small cell lung cancers (NSCLCs) preferentially use lactate as the primary carbon source, but the underlying mechanisms are not well understood. We developed a lactate‐dependent cell proliferation assay and found that dynamin‐related protein (DRP1), which is highly expressed in KRAS‐mutant NSCLC, is required for tumor cells to proliferate and uses lactate as fuel, demonstrating the critical role of DRP1 in the metabolic reprogramming...
Fri Aug 07, 2020 22:18
Abstract Ras has been found to be mutated in 30% of non‐small cell lung cancers and its mutation has been regarded as a causal factor underlying tumorigenesis. However, no successful medicine has been developed so far to inhibit Ras for lung cancer treatment. We have previously identified DHX33 as a Ras downstream effector, promoting cell cycle progression and cell growth. Here in this study, with K‐Ras (G12D); DHX33 (lox/lox) mouse model, we discovered genetic ablation of DHX33 inhibited tumor...
Fri Aug 07, 2020 22:18
Abstract The efficiency of upfront consolidation with high‐dose chemotherapy/autologous stem‐cell transplantation (HDCT/ASCT) for newly diagnosed high‐risk diffuse large B‐cell lymphoma (DLBCL) may be influenced by induction chemotherapy. To select better induction chemotherapy regimens for HDCT/ASCT, a randomized phase II study was conducted in high‐risk DLBCL patients with age‐adjusted International Prognostic Index (aaIPI) score 2 or 3. As induction chemotherapy, 6 cycles of R‐CHOP‐14 (arm A)...
Fri Aug 07, 2020 19:09
Abstract Immune checkpoint inhibitors (ICIs) have dramatically changed the strategy used to treat patients with non‐small cell lung cancer (NSCLC); however, the vast majority of patients eventually develop progressive disease (PD) and acquire resistance to ICIs. Some patients experience oligoprogressive disease. Few retrospective studies have evaluated clinical efficacy in patients with oligometastatic progression who received local therapy after ICI treatment. We conducted a retrospective analysis...
Fri Aug 07, 2020 18:38
Abstract Cancer cells have high iron requirements due to their rapid growth and proliferation. Iron depletion using iron chelators has a potential in cancer treatment. Previous studies have demonstrated that deferoxamine (DFO) specifically chelates Fe(III) and exhibited antitumor activity in clinical studies. However, its poor pharmacokinetics has limited the therapeutic potential and practical application. Although polymeric iron chelators have been developed to increase the blood retention, none...
Fri Aug 07, 2020 18:38
Abstract Wilms Tumor 1 (WT1) is an intracellular tumour‐associated antigen that remains inaccessible to antibodies. Recently, T‐cell receptor mimic antibodies (TCRm‐Abs), which recognize peptides loaded on human leukocyte antigen (HLA) with higher specificity and affinity than T‐cell receptors, have been developed as a new antibody class that can target intracellular antigens. To expand the therapeutic targets in tumours with WT1, we developed TCRm‐Abs targeting a novel HLA‐A*02:01‐restricted peptide,...
Fri Aug 07, 2020 18:38
Summary The histone demethylase JMJD1A（Jumoji domain containing 1A） is overexpressed in multiple cancers and promotes cancer progression. However, the role and mechanism of JMJD1A in gastric cancer (GC) remains poorly understood. Here, we found that JMJD1A could suppress GC cell proliferation and xenograft tumor growth. Using RNA sequencing, we identified RUNX3 as a novel target gene of JMJD1A. Mechanistically, we identified that JMJD1A up‐regulated RUNX3 through co‐activating Ets‐1 and reducing...
Thu Aug 06, 2020 22:23
Abstract The use of multi‐gene panel testing for patients with a predisposition to breast/ovarian cancer is increasing as the identification of variants is useful for diagnosis and disease management. We identified pathogenic and likely pathogenic (P/LP) variants of high and moderate risk genes using a 23‐gene germline cancer panel in 518 patients with hereditary breast and ovarian cancers (HBOC). The frequency of P/LP variants was 12.4% (64/518) for high and moderate penetrant genes, namely, BRCA2...
Thu Aug 06, 2020 15:55
Publication date: Available online 8 August 2020Source: Cancer/RadiothérapieAuthor(s): S. Racadot, B. Vérillaud, A.-A. Serre, J. Le Guevelou, L. Guzene, C. Laude, V. Grégoire, S. Deneuve, A. Larnaudie, A. Lasne-Cardon, J. Thariat
Sun Aug 09, 2020 18:46
Publication date: Available online 6 August 2020Source: Cancer/RadiothérapieAuthor(s): H. Cebula, J. Todeschi, C. Le Fèvre, D. Antoni, I. Ollivier, S. Chibbaro, G. Noël, F. Proust
Fri Aug 07, 2020 17:45
Publication date: Available online 6 August 2020Source: Cancer/RadiothérapieAuthor(s): E. Jouglar, J. Doyen, S. Supiot
Fri Aug 07, 2020 17:45
Abstract The capacity of the immune system to influence tumor progression has been a long‐standing notion that first generated clinical traction over a hundred years ago when Dr William Coley injected disaggregated bacterial components into sarcomas and noted that the ensuing inflammation commonly associated with tumor regression [1]. Since then, our understanding of the individual components and the overall interaction of the immune system has expanded exponentially. This has led to the development...
Sat Aug 08, 2020 13:03
Abstract Biometric Monitoring Technologies (BioMeTs) are becoming increasingly common to aid data collection in clinical trials and practice. The state of BioMeTs, and associated digitally measured biomarkers, is highly reminiscent of the field of laboratory biomarkers two decades ago. In this review, we have summarized and leveraged historical perspectives, and lessons learned from laboratory biomarkers as they apply to BioMeTs. Both categories share common features, including goals and roles in...
Sat Aug 08, 2020 13:02
Abstract Budigalimab (ABBV‐181) is a humanized, recombinant, Fc mutated IgG1 monoclonal antibody targeting programmed cell death 1 (PD‐1) receptor, currently in phase 1 clinical trials. The safety, efficacy, pharmacokinetics (PK), pharmacodynamics (PD), and budigalimab dose selection from monotherapy dose escalation and multi‐histology expansion cohorts were evaluated in patients with previously treated advanced solid tumors who received budigalimab at 1, 3, or 10 mg/kg intravenously every two weeks...
Sat Aug 08, 2020 13:00
Abstract We evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of AZD4831, a novel oral myeloperoxidase (MPO) inhibitor, in a randomized, single blind, placebo‐controlled study, following once daily multiple ascending dosing to steady state in healthy subjects. Target engagement was measured as specific MPO activity in plasma following ex vivo zymosan stimulation of whole blood. Except for generalized maculopapular rash in 4 out of 13 subjects receiving the two highest doses,...
Sat Aug 08, 2020 12:59
Abstract Advances in cancer treatment have significantly improved the survival of cancer patients, but unfortunately, many of these treatments also have long‐term complications. Cancer treatmement related cardiotoxicities is becoming a significant clinical problem that a new discipline, Cardio‐Oncology, was established to advance the cardiovascular care of growing cancer patient populations. Anthracyclines are a class of chemotherapeutic agents used to treat many cancers in adults and children....
Sat Aug 08, 2020 12:58
Publication date: Available online 7 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Benjamin Li, Gustavo R. Sarria, Michael Hermansen, Jackie Hao, David Martinez, Bertha Garcia, Jingxia Liu, Megan McLeod, Serguei Castaneda, Oluwadamilola T. Oladeru, Becky Lee, Gustavo J. Sarria, Hiram Gay, Indrin J. Chetty, Dante Roa
Sat Aug 08, 2020 13:13
Publication date: Available online 7 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Michele Porcu, Cinzia Solinas, Lorenzo Mannelli, Giulio Micheletti, Matteo Lambertini, Karen Willard-Gallo, Emanuele Neri, Adam E. Flanders, Luca Saba
Sat Aug 08, 2020 13:13
Publication date: Available online 7 August 2020Source: Critical Reviews in Oncology/HematologyAuthor(s): Hugues Duffau
Sat Aug 08, 2020 13:13
Opinion statement Anaplastic thyroid cancer (ATC) is a rare but very aggressive form of undifferentiated thyroid cancer. Due to its rapid rate of progression and invasive nature, ATC poses significant risks of morbidity and mortality. The cornerstone in the management of ATC remains a prompt diagnosis of the disease and timely management of complications depending on the stage of disease. Surgery continues to offer a higher chance of a cure, although not all patients are candidates...
Fri Aug 07, 2020 03:00
Opinion statement Though the majority of nervous system tumors are sporadic, several clinically relevant genetic syndromes are associated with a predisposition to tumors of the central and peripheral nervous system including neurofibromatosis type 1 (NF1), type 2 (NF2), and schwannomatosis (SWN). These represent prototypical tumor suppressor syndromes where loss of a tumor suppressor gene-protein impairs the cell’s ability to regulate cell proliferation. While clinical manifestations...
Fri Aug 07, 2020 03:00
Opinion statement Moderate-level evidence suggests that cardiac troponin and natriuretic peptides are useful for risk stratification and early identification of anthracycline cardiotoxicity; however, many of these studies used older chemotherapy regimens, and thus, the applicability to current anthracycline treatment regimens is uncertain. Further research is needed to determine optimal timing and thresholds for troponin and natriuretic peptides in anthracycline-treated patients...
Fri Aug 07, 2020 03:00
Opinion statement Robotic-assisted videothoracoscopic surgery (R-VATS) has become increasingly popular and widely used since its introduction and is nowadays considered a standard treatment approach in many centres for the treatment of non-small cell lung cancer. R-VATS was initially developed to overcome the drawbacks of VATS by offering surgeons more flexibility and three-dimensional optics during thoracoscopic surgery. The effectiveness of R-VATS lobectomy regarding oncological...
Fri Aug 07, 2020 03:00
Opinion statement The management of patients with HER2+ breast cancer has evolved significantly over the preceding decades. HER2 targeting strategies have advanced beyond focusing on the receptor alone to encompass a range of approaches. Current standard of care practices in these patients relies upon dual HER2 blockade with trastuzumab and pertuzumab in the adjuvant and metastatic settings. T-DM1 has proven particularly efficacious in patients with residual disease status post...
Fri Aug 07, 2020 03:00
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Sandra Nolte, Annika Waldmann, Gregor Liegl, Morten Aa Petersen, Mogens Groenvold, Matthias Rose, EORTC Quality of Life Group
Sat Aug 08, 2020 16:59
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Anna Szumera-Ciećkiewicz, Francesca Bosisio, Paweł Teterycz, Asier Antoranz, Francesco Delogu, Senada Koljenović, Bart A. van de Wiel, Willeke Blokx, Léon C. van Kempen, Piotr Rutkowski, Alexander Christopher van Akkooi, Martin Cook, Daniela Massi, EORTC Melanoma Group
Sat Aug 08, 2020 16:59
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Elisabeth Coart, Stefan Suciu, Pierre Squifflet, Everardo D. Saad, Andriy Moshyk, Gaetan de Schaetzen, Marc Buyse, Jeffrey S. Weber, Alexander Eggermont, Srividya Kotapati
Sat Aug 08, 2020 16:59
Publication date: September 2020Source: European Journal of Cancer, Volume 137Author(s): Andreas Teufel, Michael Gerken, Alois Fürst, Matthias Ebert, Ina Hohenthanner, Monika Klinkhammer-Schalke
Fri Aug 07, 2020 13:55
Publication date: Available online 7 August 2020Source: European Journal of Surgical OncologyAuthor(s): Jakub Kenig, Kinga Szabat, Jerzy Mituś, Maria Mitus-Kenig, Jerzy Krzeszowiak
Sun Aug 09, 2020 00:23
Publication date: Available online 6 August 2020Source: European Journal of Surgical OncologyAuthor(s): Peter Scherman, Ingvar Syk, Erik Holmberg, Peter Naredi, Magnus Rizell
Fri Aug 07, 2020 18:13
Future Oncology, Ahead of Print.
Sat Aug 08, 2020 11:59
Future Oncology, Ahead of Print.
Sat Aug 08, 2020 10:45
Future Oncology, Ahead of Print.
Fri Aug 07, 2020 05:39
Related Articles FOXD2-AS1 promotes migration and invasion of head and neck squamous cell carcinoma and predicts poor prognosis. Future Oncol. 2020 Aug 07;: Authors: Zhang L, Bo H, Chen T, Li Q, Huan Y, Zhang S Abstract Aim: To investigate the role of long noncoding RNA FOXD2-AS1 in head and neck squamous cell carcinoma (HNSCC). Materials & methods: The expression and clinical significance of FOXD2-AS1 were analyzed using data from public...
Sun Aug 09, 2020 14:39
Related Articles Making the case for EGFR TKI sequencing in EGFR mutation-positive NSCLC: a GioTag study US patient analysis. Future Oncol. 2020 Aug 06;: Authors: Feinberg B, Halmos B, Gucalp R, Tang W, Moehring B, Hochmair MJ Abstract Aim: To assess time-to-treatment failure (TTF) in US patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib-osimertinib treatment...
Sat Aug 08, 2020 14:50
Related Articles ENLIVEN study: Pexidartinib for tenosynovial giant cell tumor (TGCT). Future Oncol. 2020 08 05;: Authors: Tap W Abstract Pexidartinib is the first approved medication in the USA for people with tenosynovial giant cell tumor (TGCT). The drug was approved based on the ENLIVEN study, which looked at pexidartinib (brand name, Turalio™), a medication taken by mouth (orally) for people with TGCT (also known as giant cell tumor of...
Fri Aug 07, 2020 14:55
Journal of Adolescent and Young Adult Oncology, Ahead of Print.
Wed Aug 05, 2020 10:00
Abstract Social media messages and conversations provide an opportunity to study what users post about cancer risk and preventive behaviors. Personal stories of early detection, treatment, and survivorship are often shared. The purpose of this study was to examine the hereditary breast cancer-focused posts on the understudied visual social media platform Pinterest. Using systematic random sampling, n = 500 Pinterest posts (referred to as “pins”) were collected using the keywords...
Sat Aug 08, 2020 03:00
Pancreatic cancer (PC) is one of the most aggressive cancers and has an extremely poor prognosis worldwide. Long noncoding RNA (lncRNA) has been reported to be a potential prognostic biomarker in the initiatio...
Sat Aug 08, 2020 03:00
Providing optimal interventional oncology procedures at one of the COVID-19 referral center in Italy
Abstract The COVID-19 pandemic has deeply impacted the activity of interventional oncology in cancer centers. Since the first COVID case was diagnosed in Italy on February 21st, our Hospital, located in Milan downtown, has been at the frontline to manage this emergency and to try to ensure essential services. In the present article, we discuss the changes that need to be done for the organization, safety, and patient management in interventional oncology.
Sun Aug 09, 2020 03:00
Abstract Testicular germ cell tumours (TGCT) survivors are coping with late treatment sequelae. Testosterone deficiency may contribute to earlier onset of metabolic syndrome. The study aimed to assess connections between serum testosterone concentrations and metabolic disorders as well as body composition in TGCT survivors. 336 TGCT patients with over two years of complete post-treatment remission were divided into three groups: definite testosterone deficiency (< 8 nmol/L),...
Fri Aug 07, 2020 03:00
Abstract First-line treatment for metastatic clear-cell renal cell carcinoma patients with intermediate and poor-risk features consists of a combination of immune checkpoint inhibitors (e.g., nivolumab + ipilimumab) or immunotherapy with an anti-vascular endothelial growth factor receptor (VEGFR) drug (e.g., axitinib). The subsequent line of therapy should be determined on the basis of previous treatments and approved drugs available, based on the results of randomized clinical...
Fri Aug 07, 2020 03:00
Abstract Cancer patients are at particular risk from COVID-19 since they usually present multiple risk factors for this infection such as older age, immunosuppressed state, comorbidities (e.g., chronic lung disease, diabetes, cardiovascular diseases), need of frequent hospital admissions and visits. Therefore, in the COVID era, oncologists should carefully weigh risks/benefits when planning cancer therapies and follow-up appointments. Recently, several scientific associations...
Fri Aug 07, 2020 03:00
The cover image is based on the Original Article Fibroblast growth factor‐associated fibroblasts, stimulates growth and progression of human breast cancer cells via FGFR1 signaling by Young‐Joon Surh et al., https://doi.org/10.1002/mc.23233.
Sun Aug 02, 2020 21:22
Publication date: Available online 8 August 2020Source: Practical Radiation OncologyAuthor(s): Elizabeth B. Jeans, Yue-Houng Hu, Bradley J. Stish, Brian King, Mark Davis, William S. Harmsen, Kristin M. Fruth, Sarah E. Locher, Christopher L. Deufel, Jaden D. Evans, James A. Martenson, Scott C. Lester
Sun Aug 09, 2020 13:14
Publication date: Available online 8 August 2020Source: Practical Radiation OncologyAuthor(s): Qiongge Hu, Victoria Yu, Yingli Yang, Peng Hu, Ke Sheng, Percy Lee, Amar U. Kishan, Ann C. Raldow, Dylan P. O’Connell, Kaley E. Woods, Minsong Cao
Sun Aug 09, 2020 13:14
Publication date: Available online 7 August 2020Source: Practical Radiation OncologyAuthor(s): Paul E. Wallner, Scott Segal, David J. Laszakovits, Jeff M. Michalski, Andrea K. Ng
Fri Aug 07, 2020 13:36
Preparing patients for sexual dysfunction after radiation for anorectal cancers: a systematic review
Publication date: Available online 7 August 2020Source: Practical Radiation OncologyAuthor(s): David G. Wallington, Emma B. Holliday
Fri Aug 07, 2020 13:36
Publication date: Available online 7 August 2020Source: Practical Radiation OncologyAuthor(s): Aswin George Abraham, Nawaid Usmani, Brad Warkentin, JoAnn Thai, Jihyun Yun, Sunita Ghosh, Winson Cheung, Yuan Xu, Tirath Nijjar, Diane Severin, Keith Tankel, Alysa Fairchild, Kurian Joseph
Fri Aug 07, 2020 13:36
The Danish Head and Neck Cancer Group (DAHANCA) was founded in 1976. Over the years the group successfully conducted clinical trials and has developed national guidelines for all aspects of the treatment of head and neck cancer. The first national recommendations for radiotherapy was included as an appendix to the DAHANCA 2 and DAHANCA 5 protocols [1,2] in 1979 and 1986, respectively. A thorough description of doses and treatment fields were in 1991 included in the large DAHANCA 6&7 randomized...
Fri Aug 07, 2020 03:00
The paper entitled “Assessing the Role of Stereotactic Body Radiation Therapy in a Large Cohort of Patients With Lymph Node Oligometastases: Does It Affect Systemic Treatment's Intensification?” written by Franzese et al raised important issues regarding the use of radiotherapy in oligometastatic disease [1].
Fri Aug 07, 2020 03:00
Publication date: Available online 8 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Rose Kamal, Gaganpreet Singh, Deepak Thaper, Arun S. Oinam, Bhumika Handa, Vivek Kumar, Rakesh Kapoor
Sun Aug 09, 2020 17:51
Publication date: Available online 8 August 2020Source: Reports of Practical Oncology & RadiotherapyAuthor(s): Motoharu Sasaki, Wataru Sugimoto, Hitoshi Ikushima
Sat Aug 08, 2020 17:42
Native folded and compact intermediate states of RNA typically involve tertiary structures in the presence of divalent ions such as Mg2+ in a background of monovalent ions. In a recent study we have shown how the presence of Mg2+ impacts the transition from partially unfolded to folded states through a "push-pull" mechanism where the ion both favors and disfavors the sampling of specific phosphate-phosphate interactions (Biophysical Journal, 6: 1424-1437, 2020). To further understand the ion atmosphere...
Fri Aug 07, 2020 20:15
Publication date: October 2020Source: Cancer Epidemiology, Volume 68Author(s): Rafael De la Garza Ramos, Joshua A Benton, Y Gelfand, Murray Echt, Jessica V Flores Rodriguez, V Yanamadala, R Yassari
Sun Aug 09, 2020 18:40
Publication date: Available online 7 August 2020Source: Seminars in OncologyAuthor(s): Maria Caridad Rubio, Lizet Sanchez, Gisela Abreu-Ruíz, Walkiria Bermejo-Bencomo, Tania Crombet, Agustin Lage
Sat Aug 08, 2020 18:49
Publication date: Available online 7 August 2020Source: Seminars in OncologyAuthor(s): Laura Pala, Fabio Conforti, Maristella Saponara, Tommaso De Pas, Federica Giugliano, Emanuela Omodeo Salè, Costantino Jemos, Rubatto Marco, Agostini Andrea, Pietro Quaglino, Paolo Fava, Maria Teresa Fierro, Paola Queirolo
Sat Aug 08, 2020 18:49
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου